Seth Lederman, Tonix Pharmaceuticals CEO
Tonix cuts interim analyses of two trials, halves enrollment in one
Tonix Pharmaceuticals appears to be strapped for cash.
After cutting down on its Covid-19 work earlier this month in favor of its late-stage fibromyalgia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
